Wugen Inc., a cell therapy company based in St. Louis, has secured $115 million in funding led by Fidelity Management to advance its allogeneic, off-the-shelf CAR-T therapy for T-cell malignancies. The lead candidate WU-CART-007 is undergoing pivotal trials for relapsed or refractory T-cell acute lymphoblastic leukemia and lymphoma, with potential FDA approval targeted for 2027. This approach offers a ready-to-use alternative to patient-specific CAR-T therapies, addressing significant unmet needs in hematologic cancers.